MC2-03

POSTED: October 25, 2018 Copenhagen, October 25th, 2018 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that it has appointed Christopher S. Billis, an experienced healthcare executive within the ... READ FULL ARTICLE > POSTED: October 23, 2018 Active MC2-03 eye drop treatment resulted in a strong clinical improvement in severe dry eye patients over control arms both on CFS response (p=0.0090) and mean change from Baseline to ... READ FULL ARTICLE > READ FULL ARTICLE > POSTED: August 21, 2018 MC2-01 Cream demonstrates statistically significant superiority in both treatment success and patient reported treatment convenience compared to Taclonex® Topical Suspension. Both primary and secondary endpoints were met and a submission ... READ FULL ARTICLE > POSTED: April 2, 2018 Topline results are expected in Q3 2018 Copenhagen, April 2nd, 2018 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that the patient enrollment for the Phase ... READ FULL ARTICLE > READ MORE > READ MORE > READ MORE > READ MORE > READ MORE > READ MORE > READ MORE > READ MORE > READ MORE > READ MORE > READ MORE > READ MORE >